2013 Year in review: Clinical Development[:de]2013 Year in review: Clinical Development

  • Average clinical trials Submissions in 2013: Phase I – 314 studies per Quartile, phase II – 233 studies per Quartile, Phase III – 237 studies per Quartile;
  • R&D Spending in Pharma goes down by 5% in 2013 and in Generics jumps by 18%:
  • Major partnership: Wuintils and Merk Serono
  • Major M&As made by: Quintiles, PPD, JLL; KKR
  • Top 5 CROs accoutn for 50% of the total market and top 8 CRO account for 66% of the market.

23-01-2014 11-01-15

23-01-2014 11-01-03

More here: http://goo.gl/2kB9Vw
And Pharma Core industry Metrics: http://goo.gl/6CvhOy

[:de]
  • Average clinical trials Submissions in 2013: Phase I – 314 studies per Quartile, phase II – 233 studies per Quartile, Phase III – 237 studies per Quartile;
  • R&D Spending in Pharma goes down by 5% in 2013 and in Generics jumps by 18%:
  • Major partnership: Wuintils and Merk Serono
  • Major M&As made by: Quintiles, PPD, JLL; KKR
  • Top 5 CROs accoutn for 50% of the total market and top 8 CRO account for 66% of the market.

23-01-2014 11-01-15

23-01-2014 11-01-03

More here: http://goo.gl/2kB9Vw
And Pharma Core industry Metrics: http://goo.gl/6CvhOy

By |2016-11-16T18:35:48+00:00December 23, 2013|News|Comments Off on 2013 Year in review: Clinical Development[:de]2013 Year in review: Clinical Development

About the Author:

Professional in the integration of data-driven Risk-based Monitoring (RbM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, PharmaForum, PharmaDay, DGGF, etc. 10+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RbM research to new frontiers for CROs, pharma and biotech companies.

Upcoming Events

There are no upcoming events at this time.

Register Today!

Get Free Test Access